Ohio is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne
NCT04582383
Recruiting
Acne is common illness of adolescents and young adults which is associated with substantial morbidity. While topical treatments are often sufficient for mild acne, moderate to severe acne often requires treatment with systemic medications such as oral antibiotics, hormonal therapies such spironolactone, and isotretinoin. Sebum overproduction is fundamental to the pathogenesis of acne with associated disordered keratinization and subsequent microbial colonization and inflammation resulting in the... Read More
Gender:
FEMALE
Ages:
Between 16 years and 40 years
Trial Updated:
05/27/2025
Locations: Dermatologists of Central States, Cincinnati, Ohio
Conditions: Acne
Register for Updates
Structural Modification In Supraglottic Airway Device
NCT04498598
Recruiting
The proposed A/Z modification of a supraglottic airway (SGA) incorporates an opening in the SGA body that enables access to the endotracheal tube (ETT) through the body of the SGA without the need of using an exchange catheter, thus enabling an ETT to move in the body of the SGA and convert a supraglottic to endotracheal ventilation. In its original form an adaptor made from same material currently used in the endotracheal tubes can make ventilation through the proposed airway device possible in... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/27/2025
Locations: Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Airway Complication of Anesthesia, Ventilation Therapy; Complications, Hypoxia, Hypoventilation
Register for Updates
CHAMP T 2 Pilot of CIMT by Tele-Video
NCT06486987
Recruiting
The CHAMP-T2 study is a pilot test of the efficacy of constraint induced movement therapy (CIMT) when delivered by tele-video in the child's home or home-like environment. This study will examine the pre-, post-intervention function a hemiparetic limb in children who have hemiplegic cerebral palsy. The purpose is to provide an effect size estimate that will inform the design of a future study that will compare tele-delivered CIMT with usual and customary care.
Gender:
ALL
Ages:
Between 4 years and 10 years
Trial Updated:
05/26/2025
Locations: The Ohio State University School of Health and Rehabilitation Sciences, Columbus, Ohio
Conditions: Hemiplegic Cerebral Palsy
Register for Updates
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05257083
Recruiting
The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Multiple Myeloma
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT07002905
Recruiting
This randomized, double-blind, placebo-controlled phase IIa study is designed to evaluate the efficacy, safety, and tolerability of ASC30 Tablets and ASC30 Tablets A1.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/25/2025
Locations: Ascletis Clinical Site, Columbus, Ohio
Conditions: Chronic Weight Management
Register for Updates
Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)
NCT06999902
Recruiting
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/23/2025
Locations: Praxis Research Site, Canton, Ohio
Conditions: Focal Seizure
Register for Updates
Evaluation of Laparotomy With Trans-Amniotic Suture Placement in TTTS Surgery
NCT06991400
Recruiting
This is a randomized trial for patients that are diagnosed with Twin-Twin Transfusion Syndrome (TTTS) who are receiving a fetoscopic laser surgery to evaluate the effectiveness and safety of a laparotomy closure.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio
Conditions: Twin to Twin Transfusion Syndrome, Twin Anemia-Polycythemia Sequence
Register for Updates
Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence
NCT06862648
Recruiting
The goal of this pivotal clinical trial is to evaluate the safety and effectiveness of the SUI-100 device for the treatment of mild-to-moderate stress urinary incontinence (SUI) in females aged 22-70 years. The main questions this study aims to answer are: 1. Does treatment with the SUI-100 device reduce SUI symptoms, as measured by urine leakage. 2. Is the device safe and effective compared to the sham group? Participants will: 1. Be randomly assigned to an active or sham control group in a... Read More
Gender:
FEMALE
Ages:
Between 22 years and 77 years
Trial Updated:
05/23/2025
Locations: Helios Clinical Research, Middleburg Heights, Ohio
Conditions: Stress Urinary Incontinence (SUI)
Register for Updates
The Foods & Oil to Repair, Correct and Enhance Strength (FORCES) Study
NCT06361511
Recruiting
The proposed research is a parallel arm, randomized placebo-controlled clinical trial designed to assess changes in muscle strength, volume, fatigue resistance, and mobility in older adults after daily consumption of 12g of linoleic acid-rich oil.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
05/23/2025
Locations: The Ohio State University, Columbus, Ohio
Conditions: Sarcopenia
Register for Updates
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738
Recruiting
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Clinical Trial Site, Dayton, Ohio
Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Register for Updates
Study of AVZO-021 in Patients With Advanced Solid Tumors
NCT05867251
Recruiting
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
Register for Updates
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT05768139
Recruiting
Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Breast Cancer, Solid Tumors, Adult
Register for Updates